本帖最后由 老马 于 2012-1-13 21:20 编辑 2 H: q3 Y' Y* q- g7 ]
, o D% r% |: B. A爱必妥和阿瓦斯丁的比较
" Z2 m8 [4 Q4 c7 c% X4 d0 q1 Q
L8 P; h$ [: ?% [+ ^$ [9 @http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 g% j& S7 N9 }. R2 s# ]
% M: k2 E# O3 k) w- ]+ O% c5 h
$ @1 I" [+ B2 h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
3 x. ~6 ]- o' m9 [: B7 o; |) P==================================================7 l/ W# w9 V9 c' v; \
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)0 N' Q9 K- m- \ R& A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 t( s+ F X7 N5 _* p0 c3 F1 Z% NResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( {* o- I% ]( M! Y
|